Veinlite R®

Tail vein injection is the most common route for IV administration in rodents, but the small vessel caliber makes this technically challenging. Studies show injection failure rates of 8-17% even with experienced technicians. Failed injections lead to interstitial drug extravasation, compromising data validity and requiring subject replacement.

Research shows extravasated radiotracers, drugs, and biologics can alter experimental outcomes by up to 17% of injected dose remaining in the tail. Veinlite R helps ensure complete intravenous delivery, reducing variability and improving reproducibility—critical for regulatory submissions and publication-quality research.

Yes. When tail vein injections fail, researchers often must exclude those subjects from analysis or repeat experiments. By improving injection success rates, Veinlite R reduces data loss and may allow adequate statistical power with fewer animals—aligning with 3Rs principles (Reduce, Refine, Replace).

Critically important—yes. Black mice (C57BL/6, melanotic tumors) and pigmented rats pose significant visualization challenges, yet are among the most commonly used research models. Veinlite R's transillumination works regardless of skin pigmentation, where anatomical landmarking alone often fails.

Technical expertise significantly affects injection success rates. Veinlite R levels the playing field by making veins visible to both novice and experienced handlers, reducing training time and improving consistency across research staff—important for labs with student researchers or high turnover.

Research shows both anesthetized and conscious tail vein injection methods induce "mild" stress (temporary elevation in fecal corticosterone metabolites). By improving first-attempt success, Veinlite R minimizes procedure time and repeated attempts—both sources of animal distress that can confound behavioral or stress-related studies.

Very important application. Pharmacokinetic studies, tumor progression models, and longitudinal therapeutic trials require multiple injections in the same animal. Each failed attempt damages vessels and reduces available sites. Veinlite R helps preserve vein integrity across multiple dosing sessions.

Gene therapy vectors, monoclonal antibodies, radiopharmaceuticals, and novel therapeutics are extremely costly. Extravasation wastes these precious materials and invalidates that subject's data. Veinlite R's improved accuracy helps ensure your expensive compounds reach systemic circulation.

Yes. Models like diabetes (Ins2Akita mice) or shock often feature vein collapse and poor vessel quality. Veinlite R helps identify patent vessels in challenging disease models, making previously "impossible" IV administration achievable in relevant pathological conditions.

While Veinlite R is a procedural aid rather than an analytical instrument, improved injection success and reduced variability support data quality in GLP studies. Better procedural documentation (successful IV delivery confirmed) strengthens regulatory submissions and reduces requests for study repeats.